We published our model of DNA damage in cancer in collaboration with Industry in the British Journal of Cancer

Claire collaborated with Pharma stakeholders Merck Healthcare KGaA and Physiomics Plc to investigate the combined effect of PARP and ATR inhibitors on DNA damage in breast cancer. This study, entitled 'Semi-mechanistic efficacy model for PARP + ATR inhibitors-application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs', has just been published in the British Journal of Cancer.